Calburean P, Lupu S, Hutanu A, Oprica M, Opris D, Stan A
Sci Rep. 2024; 14(1):22171.
PMID: 39333652
PMC: 11436802.
DOI: 10.1038/s41598-024-73349-0.
Sales Conniff A, Tur J, Kohena K, Zhang M, Gibbons J, Heller L
Bioelectricity. 2024; 6(2):80-90.
PMID: 39119567
PMC: 11304878.
DOI: 10.1089/bioe.2022.0041.
Juraver-Geslin H, Devotta A, Saint-Jeannet J
Cells Dev. 2023; 176:203878.
PMID: 37742795
PMC: 10841480.
DOI: 10.1016/j.cdev.2023.203878.
Zhang J, Zhang W, Yan J, Ge Q, Lu X, Chen S
Hypertens Res. 2023; 46(8):2024-2032.
PMID: 37258625
DOI: 10.1038/s41440-023-01326-7.
Tsukamoto S, Uehara T, Azushima K, Wakui H, Tamura K
J Am Heart Assoc. 2023; 12(8):e029565.
PMID: 37066800
PMC: 10227251.
DOI: 10.1161/JAHA.122.029565.
PPAR Alpha Activation by Clofibrate Alleviates Ischemia/Reperfusion Injury in Metabolic Syndrome Rats by Decreasing Cardiac Inflammation and Remodeling and by Regulating the Atrial Natriuretic Peptide Compensatory Response.
Sanchez-Aguilar M, Ibarra-Lara L, Cano-Martinez A, Soria-Castro E, Castrejon-Tellez V, Pavon N
Int J Mol Sci. 2023; 24(6).
PMID: 36982395
PMC: 10049157.
DOI: 10.3390/ijms24065321.
Human Alpha-1 Antitrypsin Attenuates ENaC and MARCKS and Lowers Blood Pressure in Hypertensive Diabetic db/db Mice.
Lugo C, Liu L, Bala N, Morales A, Gholam M, Abchee J
Biomolecules. 2023; 13(1).
PMID: 36671451
PMC: 9856210.
DOI: 10.3390/biom13010066.
Sacubitril/valsartan, sodium-glucose cotransporter 2 inhibitors and vericiguat for congestive heart failure therapy.
Norre T, Grimm D, Simonsen U
Basic Clin Pharmacol Toxicol. 2022; 130(4):425-438.
PMID: 35128801
PMC: 9306855.
DOI: 10.1111/bcpt.13714.
Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study.
Rakugi H, Kario K, Yamaguchi M, Sasajima T, Gotou H, Zhang J
Hypertens Res. 2022; 45(5):824-833.
PMID: 35058583
PMC: 9010294.
DOI: 10.1038/s41440-021-00819-7.
Schisandrin A protects against isoproterenol‑induced chronic heart failure via miR‑155.
Gao L, Li T, Li S, Song Z, Chang Y, Yuan L
Mol Med Rep. 2021; 25(1).
PMID: 34812475
PMC: 8630813.
DOI: 10.3892/mmr.2021.12540.
The benefits of sacubitril-valsartan in patients with acute myocardial infarction: a systematic review and meta-analysis.
Xiong B, Nie D, Qian J, Yao Y, Yang G, Rong S
ESC Heart Fail. 2021; 8(6):4852-4862.
PMID: 34716749
PMC: 8712802.
DOI: 10.1002/ehf2.13677.
Cardioprotective effects of early intervention with sacubitril/valsartan on pressure overloaded rat hearts.
Li X, Braza J, Mende U, Choudhary G, Zhang P
Sci Rep. 2021; 11(1):16542.
PMID: 34400686
PMC: 8368201.
DOI: 10.1038/s41598-021-95988-3.
Narrative review: the holy grail: update on pharmacotherapy for heart failure with preserved ejection fraction.
Paz P, Mantilla B, Argueta E, Mukherjee D
Ann Transl Med. 2021; 9(6):523.
PMID: 33850920
PMC: 8039660.
DOI: 10.21037/atm-20-4602.
Narrative review in the current role of angiotensin receptor-neprilysin inhibitors.
Cruz Rodriguez J, Cu C, Siddiqui T
Ann Transl Med. 2021; 9(6):518.
PMID: 33850915
PMC: 8039652.
DOI: 10.21037/atm-20-4038.
Renal protection in chronic heart failure: focus on sacubitril/valsartan.
Pontremoli R, Borghi C, Filardi P
Eur Heart J Cardiovasc Pharmacother. 2021; 7(5):445-452.
PMID: 33822031
PMC: 8453284.
DOI: 10.1093/ehjcvp/pvab030.
Modelling the Impact of Chronic Cigarette Smoke Exposure in Obese Mice: Metabolic, Pulmonary, Intestinal, and Cardiac Issues.
Dubois-Deruy E, Remy G, Alard J, Kervoaze G, Chwastyniak M, Baron M
Nutrients. 2020; 12(3).
PMID: 32244932
PMC: 7175208.
DOI: 10.3390/nu12030827.
Design of the SILICOFCM study: Effect of sacubitril/valsartan vs lifestyle intervention on functional capacity in patients with hypertrophic cardiomyopathy.
Tafelmeier M, Baessler A, Wagner S, Unsoeld B, Preveden A, Barlocco F
Clin Cardiol. 2020; 43(5):430-440.
PMID: 32125709
PMC: 7244301.
DOI: 10.1002/clc.23346.
The Effects of Sacubitril/Valsartan on Clinical, Biochemical and Echocardiographic Parameters in Patients with Heart Failure with Reduced Ejection Fraction: The "Hemodynamic Recovery".
Romano G, Vitale G, Ajello L, Agnese V, Bellavia D, Caccamo G
J Clin Med. 2019; 8(12).
PMID: 31817815
PMC: 6947355.
DOI: 10.3390/jcm8122165.
NT-proBNP, race and endothelial function in the Multi-Ethnic Study of Atherosclerosis.
Yang S, Huang S, Daniels L, Yeboah J, Lima J, Cannone V
Heart. 2019; 105(20):1590-1596.
PMID: 31152069
PMC: 7179817.
DOI: 10.1136/heartjnl-2019-314707.
Pharmacodynamic interaction between intravenous nitroglycerin and oral sacubitril/valsartan (LCZ696) in healthy subjects.
Schuehly U, Ayalasomayajula S, Buchbjerg J, Pal P, Golor G, Prescott M
Eur J Clin Pharmacol. 2018; 74(9):1121-1130.
PMID: 29974143
DOI: 10.1007/s00228-018-2509-2.
